Health Care Delivery

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.

A new meta-analysis adds to the body of literature promoting the benefits of exercise for patients with cancer.

Within the past week, news has emerged from the Trump administration, from the HHS secretary confirmation hearings to retracted FDA guidelines on diversity in clinical trials.

Insurance coverage of preventive care is on the line as Braidwood Management v Becerra moves to the Supreme Court this year.

Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which interested investigators in potential links between these weight fluctuations and increased risk of renal events among a population with type 1 diabetes.

With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of Physicians (ACP) encompasses 3 recommendations on treating episodic migraine in adult patients in the outpatient setting.

A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access for low-income populations.

Gladys Antelo-Allen of Camden Coalition discusses a new skills lab offering accessible learning modules with 12 microlessons on best practices for approaching complex care.

Private equity hospital acquisitions in the US were associated with declines in patient care experience, particularly in overall hospital ratings, willingness to recommend, and staff responsiveness.

Patients living with HIV who were frail or prefrail had significantly poorer oral health-related quality of life compared with patients with HIV who were robust.

The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or explanation.

This week, Robert F. Kennedy Jr sat before the Senate for 2 separate hearings, to decide the fate of his confirmation as secretary of HHS.

A looming Supreme Court ruling will answer questions about the legality of the Affordable Care Act mandate for providing some preventive care services at no cost.

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.

Medicare Advantage enrollees, particularly Hispanic and Asian or Pacific Islander decedents, use less end-of-life home health care than those enrolled in traditional Medicare.

Sen. Bill Cassidy, MD, (R, Louisiana) holds a key vote on Robert F. Kennedy Jr's HHS Secretary confirmation. When Cassidy asked for a strategy on Medicare and Medicaid, Kennedy could not provide one.

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address small cell lung cancer's aggressive nature and resistance to conventional therapy.

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.